Long-term condition review

Proactive review aims to prevent deterioration, treatment harm and fragmented crisis care while supporting daily life. Its content depends on the condition, but its logic is stable: prepare, identify priorities and risk, measure control and safety, understand treatment use, agree change, and ensure follow-up. A ticked template is useful only when each item informs reasoning or reliable care.

Preparation improves value. Review prior diagnoses, trajectory, admissions, specialist plans, medicines, monitoring and outstanding results. Invite the patient to identify priorities and complete validated measures or tests when appropriate. Avoid blanket panels; every investigation needs a question, correct timing and an owner. Abnormal pre-review results need a route for action before the scheduled appointment if delay could harm.

Open with change and agenda. Ask what has improved, worsened or become hardest, then explore the outcome the person wants. Establish whether acute symptoms require a different pathway. A known diagnosis creates anchoring risk: new breathlessness in someone with asthma may be pulmonary embolism or heart failure, and fatigue in diabetes may reflect anaemia, depression or medicine harm.

Assess control using symptoms, objective data and meaningful outcomes. Exacerbations, rescue treatment, time off work, sleep, walking distance and hospital use can reveal poor control despite a reassuring single measurement. Conversely, an outlying home reading may reflect technique or device error. Compare trends and context before escalating long-term treatment.

Review implementation. Ask “How do you take these on an ordinary day?” rather than “Are you compliant?” Check inhaler, injection, monitoring or device technique directly where relevant. Explore adverse effects, beliefs, cost, supply, dexterity, cognition and competing responsibilities. Agree support that addresses the actual barrier; more information does not fix an inaccessible regimen.

Medication review links each item to indication, effectiveness, safety and patient experience. Check allergy, over-the-counter use, interactions, renal and hepatic context, monitoring and duplicate supply. Confirm specialist responsibilities and shared-care arrangements. Do not continue a high-risk medicine because another service initiated it when monitoring is absent; contact that service and act according to risk.

Prevention belongs inside review but should not crowd out the presenting concern. Check smoking, alcohol, physical activity, nutrition, vaccination and screening relevant to age, condition and risk. Use brief intervention and referral rather than moralising. Social determinants such as housing, food access, employment or caring may explain poor control and change the feasible plan.

Mental health and cognition influence every long-term condition. Ask about mood, anxiety, sleep and treatment burden when relevant. Consider capacity for specific decisions rather than inferring it from diagnosis. Involve carers with consent, and obtain the patient’s account separately where coercion or safeguarding is possible. Carer strain may threaten both people’s health.

Set goals collaboratively. Convert “improve diabetes” into a target the person can recognise, such as fewer hypoglycaemic episodes or walking to the bus stop, alongside safe clinical measures. Offer reasonable options and explain benefits, harms and effort. Record declined interventions accurately and keep future discussion open. A personalised target needs documented rationale and review.

The care plan is an operational handover. It names actions, owner, deadline, monitoring and contingency. State when the next routine review is due and what warrants earlier contact. Ensure another professional can identify which result or referral remains outstanding. Give accessible written information and verify understanding with teach-back.

Non-attendance is a safety signal when the service knows a person needs monitoring. Check contact details, language, disability, digital access, work and caring barriers. Use proportionate outreach for higher-risk treatment or disease. Repeated generic messages may document activity without creating access. Distinguish informed decline from failed contact and record escalation.

Review quality using completed pathways and outcomes, not appointment counts. Audit whether high-risk monitoring was done, reviewed, communicated and acted upon. Stratify completion by relevant inequality groups and measure patient experience. Significant deterioration, diagnostic delay or medicine harm should enter clinical governance processes, while ordinary variation drives iterative service improvement.